Pfenex Inc. (NYSEMKT:PFNX) insider Patrick K. Lucy sold 5,000 shares of Pfenex stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $10.04, for a total transaction of $50,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Pfenex Inc. (NYSEMKT:PFNX) traded up 1.29% during midday trading on Friday, hitting $10.18. 4,327 shares of the company traded hands. The stock has a market capitalization of $238.40 million, a PE ratio of 31.91 and a beta of 4.65. The stock has a 50 day moving average of $8.87 and a 200-day moving average of $8.27. Pfenex Inc. has a 52 week low of $5.78 and a 52 week high of $16.15.

Pfenex (NYSEMKT:PFNX) last posted its quarterly earnings results on Wednesday, November 9th. The company reported $1.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $2.02. The company had revenue of $48.82 million for the quarter, compared to the consensus estimate of $3.18 million. Pfenex’s quarterly revenue was up 2269.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.33) EPS. Equities analysts forecast that Pfenex Inc. will post $0.05 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Pfenex (NYSEMKT:PFNX)

Several equities analysts have recently commented on the stock. Mizuho dropped their target price on shares of Pfenex from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 9th. TheStreet upgraded shares of Pfenex from a “sell” rating to a “hold” rating in a research report on Monday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $16.00.

A number of institutional investors have recently bought and sold shares of the stock. Sio Capital Management LLC raised its position in shares of Pfenex by 31.5% in the third quarter. Sio Capital Management LLC now owns 64,556 shares of the company’s stock worth $578,000 after buying an additional 15,464 shares in the last quarter. Panagora Asset Management Inc. raised its position in shares of Pfenex by 693.6% in the third quarter. Panagora Asset Management Inc. now owns 76,459 shares of the company’s stock worth $684,000 after buying an additional 66,824 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Pfenex by 92.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 22,117 shares of the company’s stock worth $198,000 after buying an additional 10,636 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Pfenex during the third quarter worth $128,000. Finally, Morgan Stanley raised its position in shares of Pfenex by 31.1% in the third quarter. Morgan Stanley now owns 14,812 shares of the company’s stock worth $133,000 after buying an additional 3,517 shares in the last quarter.

Pfenex Company Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Stock Ratings for Pfenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc. and related stocks with our FREE daily email newsletter.